Bio News
SK Bioscience reported an operating loss of 44.5 billion won in the first quarter, widening its deficit despite a 9% increase in revenue. The company’s consolidated first-quarter revenue totaled 168.6 billion won, up 9.1% from the same period a year earlier, while its operating loss increased 194.4%. During the same period, net loss was provisionally estimated at 36.1 billion won, an increase of more than 788% from 4 billion won a year earlier.
BIOBOOK TEAM
biobookmedia@biobook.co.krBrazilian Health Regulatory Agency Approves Gazyva for a New Indication in Systemic Lupus Erythematosus
Belgium’s Amadcell acquires two Lakefront CAR T therapies for up to $230 million
OrbiMed Raises $3 Billion, Its Largest Asia Fund to Date
UK Researchers Identify New Mechanism of Antifungal Drug Resistance in Candida auris
AstraZeneca Signs $1.5 Billion AI Drug Target Discovery Deal With Insitro
Hyundai Pharmaceutical’s Third-Quarter Operating Profit Reaches KRW 5.937 Billion, Up 44% Year Over Year
